B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells

Jun Sik Lee,*1,2 Lisa Scandiuzzi,*1 Anjana Ray,* Joyce Wei,† Kimberly A. Hofmeyer,* Yael M. Abadi,* Ping Loke,‡ Juan Lin,§ Jianda Yuan,† David V. Serreze,¶ James P. Allison,† and Xingxing Zang*

B7x (B7-H4 or B7S1) is the seventh member of the B7 family, and its in vivo function remains largely unknown. Despite new genetic data linking the B7x gene with autoimmune diseases, how exactly it contributes to peripheral tolerance and autoimmunity is unclear. In this study, we showed that B7x protein was not detected on APCs or T cells in both human and mice, which is unique in the B7 family. Because B7x protein is expressed in some peripheral cells such as pancreatic β cells, we used a CD8 T cell-mediated diabetes model (AI4αβ) in which CD8 T cells recognize an endogenous self-Ag, and found that mice lacking B7x developed more severe diabetes than control AI4αβ mice. Conversely, mice overexpressing B7x in the β cells (Rip-B7xAI4αβ) were diabetes free. Furthermore, adoptive transfer of effector AI4αβ CD8 T cells induced diabetes in control mice, but not in Rip-B7xAI4αβ mice. Mechanistic studies revealed that pathogenic effector CD8 T cells were capable of migrating to the pancreas but failed to robustly destroy tissue when encountering local B7x in Rip-B7xAI4αβ mice. Although AI4αβ CD8 T cells in Rip-B7xAI4αβ and AI4β mice showed similar cytotoxic function, cell death, and global gene expression profiles, these cells had greater proliferation in AI4αβ mice than in RIP-B7xAI4αβ mice. These results suggest that B7x in nonlymphoid organs prevents peripheral autoimmunity partially through inhibiting proliferation of tissue-specific CD8 T cells, and that local overexpression of B7x on pancreatic β cells is sufficient to abolish CD8 T cell-induced diabetes. The Journal of Immunology, 2012, 189: 4165–4174.

The interaction between the B7 family and their receptor CD28 family generates positive costimulation and negative coinhibition, which are necessary for the regulation of peripheral T cell activation and tolerance. B7x (B7-H4 or B7S1) is the seventh member of the B7 family and is able to inhibit in vitro T cell proliferation and cytokine production in the presence of TCR signaling (1–3). In contrast with classical B7-1 and B7-2, whose expression is generally limited to professional APCs in lymphoid organs, B7x mRNA is detected more highly in nonlymphoid organs than lymphoid organs (1, 4). The combination of the in vivo mRNA expression pattern and the in vitro T cell coinhibitory capability of B7x suggests that the B7x pathway may be important in regulating tolerance and autoimmunity in nonlymphoid organs.

Most autoimmune diseases are genetically complex, and variation at a large number of genes influences disease susceptibility and progression (5, 6). Type 1 diabetes (T1D), an autoimmune disease, is characterized by self-reactive T cells that recognize and destroy the insulin-producing β cells of the pancreas, resulting in a breakdown of glucose homeostasis. Genetic mapping and gene-phenotype studies in mice and humans have revealed that, in addition to the MHC locus, >20 insulin-dependent diabetes loci contribute to T1D development (7). One of these loci, the insulin-dependent diabetes 10 locus on mouse chromosome 3, contains the B7x gene (8), suggesting a potential role of B7x in T1D. Murine studies support this notion because B7x suppresses CD4 T cell-mediated T1D (4). Juvenile idiopathic arthritis, another autoimmune disease, is the most common chronic rheumatic disease of childhood, and the majority of genetic risk factors remain to be elucidated. Recently, a genome-wide association analysis identified 10 single-nucleotide polymorphisms in noncoding regions of the B7x gene that are strongly associated with juvenile idiopathic arthritis (9). In addition, two single-nucleotide polymorphisms in the B7x gene are significantly associated with increased serum IgE in children (10). Despite these recently discovered genetic data linking the B7x gene to different autoimmune diseases, it is unclear how B7x contributes to peripheral tolerance and autoimmunity.

In this study, we found that endogenous B7x protein was not detected on APCs and T cells of either human or mouse. Because B7x protein is expressed on pancreatic β cells (4), we crossed B7x-deficient mice (B7x−/−) or transgenic mice overexpressing B7x in pancreatic β cells (Rip-B7x) (4) with CD8 TCR transgenic mice
(AI4ab) specific for an Ag expressed by pancreatic β cells (11, 12) to study the role of tissue-expressed B7x in CD8 T cell-mediated organ-specific autoimmune destruction. B7x−/− mice developed exacerbated diabetes induced by β cell Ag-specific AI4ab CD8 T cells, whereas overexpression of B7x on pancreatic β cells was sufficient to completely abrogate diabetes induced by the same Ag-specific CD8 T cells. In addition, Rip-B7x transgenic mice were resistant to diabetes induced by adoptive transfer of effector AI4ab CD8 T cells. The absence of diabetes in Rip-B7x transgenic mice was not due to a primary defect in cytotoxic function of pathogenic CD8 T cells, but rather was most likely due to the inhibitory effect of tissue-expressed B7x on proliferation of pathogenic CD8 T cells.

Materials and Methods

Mice

B7x−/−, Rip-B7x, AI4ab/B6. H2b77/77, and AI4ab/B6. H2b77/77 mice were previously described (4, 13). B7x−/− mice were crossed to C57BL/6. H2b77/77 background and then crossed to AI4ab/B6. H2b77/77 or AI4ab/B6. H2b77/77 to get B7x−/−/AI4ab/B6. H2b77/77 or B7x−/−/AI4ab/B6. H2b77/77, which were further intercrossed to generate B7x−/−/AI4ab/B6. H2b77/77. Rip-B7x mice were crossed to C57BL/6. H2b77/77 background and then crossed to AI4ab/B6. H2b77/77 or AI4ab/B6. H2b77/77 to get Rip-B7x/Al4ab/B6. H2b77/77 or Rip-B7x/Al4ab/B6. H2b77/77, which were further intercrossed to generate Rip-B7x/Al4ab/B6. H2b77/77. All mice were maintained under specific pathogen-free conditions at the Albert Einstein College of Medicine following protocols approved by the Institutional Animal Care and Use Committee.

Abs and tetramer for flow cytometry

Cells were preincubated with anti-CD16/CD32 and then stained with Abs against B7x (clones 9 and H74, [eBioscience]; BA2F154 [R&D Systems]; our own clone 19D6, 15D12, 12D11, and 1H3 [4]) or other markers (eBioscience, BD Pharmingen, AbD Serotec). For intracellular staining, cells were fixed, permeabilized, and then stained. Alexa 647-conjugated MimA2/YA1YNYLELH-2D3 tetramer was made by the National Institutes of Health Tetramer Core Facility. Alive and dead cells were detected using LIVE/DEAD marker (Invitrogen). Samples were examined using a FACScalibur or LSRII (BD Biosciences) with subsequent analysis of data in FlowJo (Tree Star).

Stimulation of immune cells

Human PBMCs were isolated by Ficoll-Hypaque gradient centrifugation, and T cells were stimulated with PHA (5 μg/ml) for 72 h or PMA (50 ng/ml) and ionomycin (1 μM/ml) for 48 h. B cells were purified from PBMC by CD19 MicroBeads (Miltenyi Biotec) and activated with LPS (60 μg/ml) for 48 h. Monocytes were purified from PBMC with CD19 MicroBeads (Miltenyi Biotec) and activated with LPS (0.5 μg/ml) and ionomycin (1 μg/ml) for 48 h. B cells were purified from PBMC with CD19 MicroBeads (Miltenyi Biotec) and activated with LPS (0.5 μg/ml) and ionomycin (1 μg/ml) for 48 h. Mouse T cells were purified with Con A (0.02–20 μg/ml) or plate-coated anti-CD3/CD28 (0.1–40 μg/ml) for 72 h, or PMA/ionomycin for 48 h. Th1 and Th2 cell lines were generated from OT-II mice as described previously (15). B cells were activated with LPS (2.5–80 μg/ml) or anti-IgM (IgM α/β) fragment (2.5–80 μg/ml) for 72 h, or PMA/ ionomycin for 48 h. Nematode Brugia malayi infection-induced alternatively activated macrophages and DCs were obtained as described previously (16). Infiltrating immune cells in the lung from 4T1-induced lung metastasis or Streptococcus pneumoniae-induced lung (17) infection were also used.

Assessment of diabetes development

Diastix (Bayer) testing strips were used to determine urine glucose levels in mice. Mice were considered to be diabetic after two consecutive measurements exceeding 250 mg/dl.

Histology and immunohistochemistry

Mouse organs were fixed with 4% paraformaldehyde and embedded in paraffin. Sections were stained with H&E or Gomori aldehyde-fuchsin (GAF) for pancreatic β cells by the Histotechnology and Comparative Pathology Core Facility. For immunohistochemical staining, tissues were collected from mice and fixed in 10% neutral-buffered formalin (Fisher) before paraffin embedding. After clearing in xylene washes and rehydration, Ag retrieval was performed in a vegetable steamer in Tris/EDTA Ag retrieval solution. Sections were biotin blocked using the ScyTek Biotin Blocking kit; then normal blocking was done using horse serum (Vector Labs). Sections were incubated with a biotinylated anti–B7-H4 Ab or isotype IgG control (R&D Systems) overnight at 4°C and then blocked for endogenous peroxidase for 10 min in 1% H2O2. Sections were incubated in ABC reagent (Vector Labs) for 20 min; then the tyramide amplification kit (Invitrogen) was used, followed again with the ABC reagent for 20 min. Sections were developed with the DAB kit (Vector Labs), counterstained with hematoxylin, dehydrated, cleared in xylene, and mounted.

Adaptive transfer of AI4ab CD8 T cells

A total of 2 × 106 splenocytes from AI4ab/B6b77/77 mice were injected i.v. into sublethally irradiated mice (750 rad) as described previously (18), and recipients were monitored for diabetes. Alternatively, splenocytes from AI4ab/B6b77/77 mice were stimulated with MimA2 peptide (3.5 μg/ml), irradiated C57BL/6. H2b77/77 splenocytes (2000 rad), LPS (0.18 μg/ml), and IL-2 (10 μ/ml) for 5 d. The activated AI4ab CD8 T cells were then transferred i.v. into mice at 5 × 106 per mouse, and recipients were monitored for diabetes.

Cell-mediated cytotoxicity assay

CD8 T cells (>95% AI4ab cells) from AI4ab and Rip-B7x AI4ab mice were purified with Miltenyi beads and then incubated with MimA2 peptide-pulsed and PKH-26/Cy5–labeled C57BL/6. H2b77/77 splenocytes for 4 h. The percent-specific cytotoxicity was determined as described previously (19).

Microarray analysis

Pancreata from mice were chopped in RPMI with 5% FCS and proteinase inhibitors, and then incubated at 37°C in digestion buffer (50 ml RPMI, 5% FCS, 1 ml collagenase IV, 2 U/ml DNase I, and 100 μ/ml heparin) for 10 min. After filtering through 40-μm strainers, single-cell suspensions were pooled and AI4ab CD8 T cells were isolated by FACS sorting using anti-CD8 Ab and MimA2/H-2Db tetramer (99% purity of sorted AI4ab cells), and then immediately placed in RNAalater (Qiagen). Samples were assessed with Affymetrix Mouse Gene 1.0 ST array chips by Genomics Core Facility. Microarray data were deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE40225. The array data were imported into Expression Console v1.1 (Affymetrix), normalized after quality control, and ranked using LIMMA (R package) analysis for comparison of different groups. Three technical replicates for each group were averaged for fold change, and statistical significance was set to p < 0.05 by applying t test analysis adjusted for multiple comparisons.

Statistical analyses

Statistical significance was calculated with the unpaired t test using Prism software version 5.0b (GraphPad). A p value <0.05 was considered statistically significant.

Results

B7x protein is not expressed on APCs or T cells in both human and mouse

Because all other B7 family members are mainly expressed on APCs, we wanted to determine whether B7x protein was detected on human APCs and T cells. Using a panel of mAbs and a polyclonal Ab, we failed to detect B7x protein with flow cytometry on B cells, monocytes, and T cells from PBMC before or after stimulation: monocytes with LPS/IFN-γ, B cells with LPS or PMA/ionomycin, and T cells with PHA or PMA/ionomycin (Table I). These stimuli were able to upregulate the expression of B7-H1 (PD-L1) or B7-2 (Supplemental Fig. 1A–C), but not B7x (Table I). Similarly, no B7x protein was detected on human immature DCs, immature LCs, as well as mature DCs or mature LCs stimulated with cytokine mixture, CD40L, LPS, or PMA/ionomycin (Table I). In contrast, B7-2 was significantly upregulated on mature DCs and LCs as the results of activation and maturation (Supplemental Fig. 1D, 1E). As a positive control, anti-B7x Abs stained a human
B7x-transfected 293 cell line (Supplemental Fig. 1F). We recently reported that among 103 ovarian borderline tumors and carcinomas tested, all expressed B7x (20). The tumor-infiltrating lymphocytes we observed in some of these samples, however, were B7x negative.

We recently showed that murine DCs or macrophages do not express B7x protein in vitro even after culturing in various stimulating, suppressive, and maturation conditions (4). We further isolated B and T cells, and incubated them with various stimuli: B cells with LPS, anti-IgM F(ab')2, PMA/IONOMYCIN; and T cells with Con A, plate-bound anti-CD3/CD28, PMA/IONOMYCIN, as well as T cell subpopulations of Th1, Th2, and regulatory T cells. We did not detect B7x protein expression on these stimulated cells (Table I). In contrast, PD-1 was induced on activated T and B cells (Supplemental Fig. 2A, 2B). In addition, we were unable to detect B7x protein in DCs and alternatively activated macrophages from chronic Brugia malayi infection (16) or immune cells from Streptococcus pneumoniae-induced lung infection (17). Leukocytic infiltrates in 4T1-induced lung metastatic cancer were also B7x negative (Table I). In contrast, DCs and alternatively activated macrophages from chronic Brugia malayi infection expressed high levels of PD-L2 (Supplemental Fig. 2C). As a positive control, a BWZ cell line overexpressing mouse B7x stained well with anti-B7x in flow cytometry (Supplemental Fig. 2D). Collectively, these results demonstrate that, unlike any other B7 molecules, endogenous B7x protein is not expressed in the immune cells of either human or mouse.

More aggressive CD8 T cell-mediated tissue destruction in B7x-deficient mice

B7x protein is expressed in mouse pancreatic β cells (4) and human pancreas (21). To dissect the in vivo function of B7x, we generated B7x−/− mice, which were born at the expected Mendelian frequency and were of normal size, maturation, and fertility. We found that B7x−/− mice developed more severe diabetes than wild-type control mice after the injection of activated diabetogenic BDC2.5 CD4 T cells (4). It is unknown, however, whether tissue-expressed B7x is able to regulate CD8 T cell function in vivo. Therefore, we investigated the function of endogenous B7x in CD8 T cell-mediated tissue destruction. To address this, we took advantage of AI4αβ transgenic mice that carry the rearranged TCR α- and β-chain genes (Vα8Vβ2) from an NOD-derived MHC class I-restricted CD8 T cell clone (11). AI4αβ CD8 T cells recognize an epitope from dystrophia myotonica kinase expressed by pancreatic β cells (12) and are capable of killing β cells and mediating overt diabetes on the C57BL/6.H2b/g7 background in the complete absence of CD4 T cell help (22). We crossed B7x−/− mice to the C57BL/6.H2b/g7 background, then crossed to AI4αβ mice (Fig. 1A) and monitored diabetes development in B7x−/−AI4αβ and AI4αβ mice (Fig. 1B–D). We observed that the disease onset (the first day when glucose level exceeded 250 mg/dl) and the point at which 100% of mice had developed diabetes came ~2–4 d earlier in B7x−/−AI4αβ mice than AI4αβ controls (Fig. 1B). This trend resulted in higher average glucose levels in B7x−/−AI4αβ mice (Fig. 1C). Furthermore, more aggressive disease progression in B7x−/−AI4αβ mice resulted in earlier mortality; these mice started to die roughly 16 d earlier than controls (Fig. 1D). Considering that naïve B7x−/− mice were healthy and that B7x deficiency in AI4αβ mice resulted in more aggressive disease, these results suggest that the role of B7x in T cell regulation mainly lies in disease progression, but not in the naive steady-state.

Local expression of B7x completely abrogates CD8 T cell-mediated diabetes

In AI4αβ mice, CD8 T cells are able to destroy pancreatic β cells and induce an aggressive onset of diabetes with 100% of mice exhibiting disease, and all mice ultimately die within 2 mo. B7x−/−AI4αβ mice developed T1D earlier even than AI4αβ control mice. Moreover, nearly half of B7x−/−AI4αβ mice died by day 12 (Fig. 1D), which made it extremely difficult to obtain enough AI4αβ CD8 T cells from these mice for further functional assays. Therefore, we next examined whether B7x overexpressed in pancreatic β cells could regulate CD8 T cell-mediated tissue destruction and disease development in vivo. Rip-B7x transgenic mice overexpress B7x in pancreatic β cells under the rat insulin II promoter (4). We crossed Rip-B7x mice to the C57BL/6.H2b/g7 background, then crossed to AI4αβ mice (Fig. 1A) and monitored diabetes in Rip-B7xAI4αβ and AI4αβ mice (Fig. 1B–D). We found that although Rip-B7xAI4αβ mice did not succumb to diabetes and remained healthy indefinitely, all AI4αβ mice experienced development of diabetes and died within 50 d. Compared with diabetes-free Rip-B7xAI4αβ mice, AI4αβ mice had lower body weight and smaller pancreas, pancreatic lymph nodes (PLNs), and spleen. These findings clearly demonstrate that local overexpression of B7x is sufficient to completely ablate tissue destruction induced by autoimmune CD8 T cells in vivo.

Pathogenic CD8 T cells infiltrate to the pancreas in B7x-transgenic mice

During the pathogenesis of diabetes, islet Ag-specific T cells are activated in PLNs by APCs (23–25). Subsequently, T cells infiltrate into pancreatic islets (insulitis) and eventually cause overt diabetes. One interpretation for the absence of diabetes in Rip-
B7xAI4αβ mice is that pathogenic CD8 T cells are unable to migrate from lymphoid tissues into the pancreas in B7x-transgenic mice. To assess this possibility, we first examined the development of insulitis in Rip-B7xAI4αβ and AI4αβ mice. H&E-stained pancreatic sections from around 30-d-old mice showed that Rip-B7xAI4αβ mice, like naive C57BL/6.H2g7/g7 mice, maintained normal islet architecture, whereas AI4αβ mice lost almost all islets (Fig. 2A, upper panels). However, ~23% of islets in transgenic Rip-B7xAI4αβ mice had leukocytic infiltrates. We further used GAF staining to visualize β cells and found that the majority of islets in Rip-B7xAI4αβ mice were intact and completely GAF-stained (Fig. 2A, middle panels); however, some islets had only

**FIGURE 1.** B7x deficiency leads to exacerbated diabetes, whereas B7x overexpression in pancreatic β cells abrogates disease induced by CD8 T cells recognizing an endogenous self-Ag in the pancreas. (A) Scheme for generation of B7x−/−AI4αβ, Rip-B7xAI4αβ, and AI4αβ mice on C57BL/6.H2g7/g7 background. (B–D) B7x−/−AI4αβ, Rip-B7xAI4αβ, and control AI4αβ mice were examined for diabetes incidence (B), glucose measurements (C), and survival (D). n = 8–10 mice/group. Data are representative of three independent experiments and are presented as means ± SEM.

**FIGURE 2.** Pathogenic CD8 T cells infiltrate into the pancreas in B7x-transgenic mice. (A) H&E- and GAF-stained pancreatic sections from C57BL/6.H2g7/g7, AI4αβ, and RIP-B7xAI4αβ mice. (B) H&E-stained sections of brain, kidney, liver, and lung from C57BL/6.H2g7/g7, AI4αβ, and RIP-B7xAI4αβ mice. n = 3–5 mice per group, data represent one of three independent experiments. Scale bars, 50 μm (A); 200 μm (B). Original magnification ×20 (A); ×5 (B).
phenotypic difference between Rip-B7xAI4αβ mice barely contained intact islets; therefore, no GAF* staining was detected (Fig. 2A). Unlike the pancreas, no notable leukocyte infiltration was observed in other nons lymphoid organs such as the brain, kidney, liver, and lung in both Rip-B7xAI4αβ and AI4αβ mice (Fig. 2B). These observations indicate that leukocytes are able to specifically infiltrate the pancreas of Rip-B7xAI4αβ mice.

To obtain a more complete picture, we analyzed the leukocytic infiltrates from the pancreas. Single-cell suspensions prepared from the pancreas, PLN, and spleen were stained with MimA2/H2-Db tetramer and anti-CD8 Ab to detect AI4αβ cells (18), and with lineage-specific Abs to examine other immune cells. More than 95% of CD8 T cells were tetramer* in AI4αβ and Rip-B7xAI4αβ mice. Flow cytometry analysis showed that there were fewer AI4αβ cells in the pancreas and PLN of Rip-B7xAI4αβ mice than AI4αβ mice (Fig. 3A), although the difference did not reach statistical significance. In addition, there was no significant difference in the number of other immune cells, including CD4 T cells, B cells, NK cells, DCs, macrophages, and neutrophils in the pancreas, PLN, and spleen between Rip-B7xAI4αβ and AI4αβ mice. These data suggest that the infiltration of other immune cells in the pancreas does not significantly contribute to the phenotypic difference between Rip-B7xAI4αβ and AI4αβ mice.

Because ~23% of islets in transgenic Rip-B7xAI4αβ mice had leukocytic infiltrates, we asked whether the infiltrate could affect the B7x expression in islets of these mice. Immunohistochemistry analysis revealed that most islets had strong expression of B7x protein throughout (Fig. 3B, upper panels); however, in islets with leukocytic infiltrates, B7x+ cells were confined to areas devoid of infiltrates (Fig. 3B, upper panels), indicating a reverse correlation between B7x expression and leukocytic infiltration. As expected, pancreatic islets in AI4αβ mice were barely detectable, with no obvious staining for B7x (Fig. 3B, lower panels).

To examine whether local overexpression of B7x is able to inhibit effector CD8 T cell-induced autoimmune damage, we used an adoptive transfer model of diabetes in which splenocytes from AI4αβ mice induced the disease in irradiated recipients (18). Splenocytes were isolated from 25- to 30-d-old AI4αβ mice and transferred to sublethally irradiated mice at 2 × 10⁷ cells/mouse (Fig. 4A). C57BL/6.H2g7/g7 recipients started to develop diabetes around day 10, and all progressed to the disease around day 20 (Fig. 4B, 4C). In contrast, none of RIP-B7x recipients on C57BL/6.H2g7/g7 background succumbed to the disease (Fig. 4B, 4C). H&E-stained pancreatic sections from around 30 d after splenocyte transfer revealed that Rip-B7x mice had fewer leukocytic infiltrates and more normal islet architecture than C57BL/6.H2g7/g7 mice (Fig. 4D). Similarly, Rip-B7x recipients exhibited more GAF+ staining than C57BL/6.H2g7/g7 recipients (Fig. 4D).

Irradiation of mice usually induces profound changes including cell death and inflammation, which could complicate behavior and function of adoptively transferred T cells in vivo. Therefore, we developed a new “clean” system in which adoptively transferred CD8 T cells were capable of yielding 100% diabetes in naïve, nonirradiated recipients. Splenocytes isolated from AI4αβ mice were activated with MimA2 peptide and APCs in the presence of IL-2 and LPS for 5 d, which led to the expansion of effector AI4αβ cells with low CD62L expression (data not shown). Adoptive transfer of 5 × 10⁶ effector AI4αβ cells per mouse (Fig. 5A) rapidly induced diabetes in all C57BL/6.H2g7/g7 recipients within 1 wk (Fig. 5B, 5C). Again, none of the RIP-B7x recipients on C57BL/6.H2g7/g7 background succumbed to the disease (Fig. 5B, 5C). Thirty days after adoptive transfer of effector AI4αβ cells, we further prepared single-cell suspensions from pancreas, PLN, and spleen to identify AI4αβ cells using MimA2/H2-Dα tetramer and an anti-CD8 Ab. Compared with control C57BL/6.H2g7/g7 mice, Rip-B7x mice had significantly lower numbers of AI4αβ cells in the pancreas (Fig. 5D).

Taken together, the results from these two adoptive transfer models of diabetes demonstrate that B7x overexpressed in pancreatic β cells abrogates diabetes by halting effector CD8 T cell-mediated tissue destruction.

Global gene expression and functional molecules in pancreatic CD8 T cells

To further understand the molecular mechanisms by which local expression of B7x abrogates effector CD8 T cell-mediated tissue destruction, we undertook a microarray analysis of AI4αβ cells from the pancreas. Single-cell suspensions prepared from the pancreas from ten 25- to 30-d-old AI4αβ or Rip-B7xAI4αβ mice were pooled, and AI4 CD8 T cells were isolated by FACs sorting using MimA2/H2-Dα tetramer and an anti-CD8 Ab. Triplicate samples from a total of 20–30 AI4αβ or Rip-B7xAI4αβ mice...
were analyzed with microarrays containing >35,000 mouse transcripts. By using high-stringency criteria for evaluation ($p < 0.05$, and changes of $\geq 2$-fold as cutoffs), we found, unexpectedly, that only one gene transcript, Ccl3 (MIP-1α), was differentially regulated in pancreatic AI4β CD8 T cells in Rip-B7xAI4β mice versus control AI4β mice (Fig. 6A, 6B). Consistent with the microarray results, RT-PCR detected a significant amount of Ccl3 mRNA in pancreatic AI4β CD8 T cells from Rip-B7xAI4β mice, but not from AI4β mice (Fig. 6B). These data show that pancreatic effector CD8 T cells in Rip-B7xAI4β and AI4β mice have a similar pattern of global gene expression, and that genetic signatures of these T cells are nearly indistinguishable.

We next analyzed some key functional molecules in AI4β T cell at the protein level. Single-cell suspensions prepared from the pancreas, PLN, and spleen were stained with Mm4A2/H2-Db tetramer for AI4β cells and with Abs against functional molecules. Granzyme B (GzmB) is the most abundant component of the cytolytic granule and is a major part of the cytolytic mechanisms enabled by perforin (26). IFN-γ upregulates MHC class I expression on the β cells (27, 28), and together with IL-1β or TNF-α, induces β cell apoptosis (29). IFN-γ is considered traditionally as a proinflammatory factor. However, studies also reveal IFN-γ’s anti-inflammatory effects in some autoimmune diseases (30, 31). We examined these two cytotoxic effector molecules in...
These results are consistent with the microarray data and suggest of Bcl-2 protein in AI4ab and death (35). Again, intracellular staining showed a similar level expression of Bcl-2, a molecule involved in CD8 T cell survival of mice had low percentages of pancreatic IFN-γ did not reach significant difference (Fig. 6C). Because both groups B7xAI4 served significant, yet comparable, percentages of PD-1 + AI4 surface of CD8 T cells induces cell exhaustion (33, 34). We observed significant, yet comparable, percentages of PD-1+ AI4αβ cells in both groups of mice (Fig. 6C). We also looked at the expression of Bcl-2, a molecule involved in CD8 T cell survival and death (35). Again, intracellular staining showed a similar level of Bcl-2 protein in AI4αβ cells in both groups of mice (Fig. 6C).

These results are consistent with the microarray data and suggest that AI4αβ CD8 T cells in both Rip-B7xAI4αβ and AI4αβ mice have a similar functional status.

Proliferation and cytotoxic function of AI4αβ CD8 T cells in Rip-B7xAI4αβ mice

Given that all AI4αβ mice experienced development of diabetes and died, whereas Rip-B7xAI4αβ mice were healthy, we next examined whether AI4αβ CD8 T cells in Rip-B7xAI4αβ mice were fully functional. We purified AI4αβ cells from mice and examined their cytotoxic activity with MimA2 peptide-pulsed C57BL/6.H2-Dab splenocytes as targets. AI4αβ T cells in Rip-B7xAI4αβ and AI4αβ mice showed similar CTL activity (Fig. 7A), suggesting that AI4αβ T cells in Rip-B7xAI4αβ mice maintain normal cytotoxic function. We further examined in vivo AI4αβ T cell proliferation by measuring intracellular Ki-67, a cell proliferation marker. Single-cell suspensions prepared from the pancreas, PLN, and spleen were stained with MimA2/H2-Dab tetramer and an anti-CD8 Ab to detect AI4αβ cells, as well as an anti-Ki-67 Ab to identify proliferating cells. We found that AI4αβ CD8 T cells in AI4αβ mice had greater proliferation than those in RIP-B7xAI4αβ mice (Fig. 7B) but showed similar percentages of cell death in both groups of mice (Fig. 7C). These data suggest that B7x inhibits Ag-specific CD8 T cell proliferation in vivo but does not affect the cell death of those pathogenic cells. These results also indicate that the resistance of Rip-B7xAI4αβ mice to diabetes is partially due to the inhibitory effect of B7x on proliferation of pathogenic CD8 T cells.

Discussion

The expression of B7x protein has been reported inconsistently, with some studies showing B7x is induced on some immune cells (2, 3) and others reporting immune cells are B7x negative (36). To resolve these discrepancies, we used multiple specific mAbs and polyclonal Abs to inspect B7x protein on immune cells. Although extensively examined, we were unable to detect B7x protein in human and mice immune cells under various stimulations and during infection or cancer. Therefore, we concluded that B7x protein was not expressed in immune cells. By contrast, canonical members of the B7 family such as B7-1 and B7-2 are highly expressed in APCs (37) and activated T cells (38). B7h (ICOS ligand) is also expressed in APCs (39, 40). Whereas PD-L2 (B7-DC) expression is mostly restricted to DCs and macrophages (41), PD-L1 (B7-H1) is widely expressed on hematopoietic cells (41, 42) and several parenchymal tissues (43, 44). B7-H3 can be in-
Others have shown that B7x protein is expressed in mice pancreatic β cells and in human pancreas (21), and that B7x can inhibit CD4 T cell-mediated diabetes and experimental autoimmune encephalomyelitis (4). We now further reveal that B7x expressed in pancreatic β cells has an important role in CD8 T cell-mediated pancreas-specific damage. B7x−/− AI4αβ mice exhibited even more aggressive disease than AI4αβ mice. As a consequence, B7x−/− AI4αβ mice developed earlier lethality than AI4αβ mice. These findings unveil a crucial immunosuppressive checkpoint in which tissue-expressed B7x can inhibit self-reactive, tissue-specific CD8 T cells, and thus prevent an autoimmune disorder. Given that B7x is not expressed in immune cells, these observations also imply a B7x-dependent suppressive mechanism that operates at the effector T cell phase, not at the stage of T cell priming. Because the loss of B7x expression resulted in more severe diabetes, we also examined whether the overexpression of the molecule could prevent disease. We found that the overexpression of B7x in the pancreatic islet β cells of AI4αβ mice resulted in complete abrogation of diabetes. However, the overexpression of B7x did not prevent insulitis. Rather, islet Ag-specific CD8 T cells were activated in PLN and further migrated into the pancreas in B7x-transgenic mice. Indeed, in two adoptive transfer models of diabetes, the injection of activated diabetogenic CD8 T cells into B7x-transgenic animals generated insulitis but failed to induce diabetes. These results emphasize the inhibitory effect of B7x on pathogenic effector CD8 T cells.

The pathogenesis of most autoimmune diseases involves multiple steps. In T1D, the insulitis phase can persist for long periods of time in humans and mice; many such prediabetic individuals never progress to overt diabetes. It is unclear which mechanisms control the conversion from the prediabetes insulitis to the diabetic state. Because overexpression of B7x in the β cells did not prevent insulitis but abrogated the progression to disease, it is conceivable that the level of B7x protein in the pancreas may be one of the factors that determine whether the insulitis phase proceeds to the diabetic state. It is known that immune cells capable of recognizing self-Ags exist in some normal individuals without causing harmful diseases. Future investigation is clearly warranted to dissect whether coinhibitory B7 molecules, such as B7x or PD-L1, prevent self-reactive immune cells in these individuals from progressing to disease by upregulating their expression in tissue cells.

Multiple mechanisms have been proposed for the peripheral tolerance of self-reactive CD8 T cells, including anergy (50), clonal deletion (50), and exhaustion (34). In the absence of the B7-1/B7-2/CD28 pathway, Ag encounter can result in T cell anergy or deletion, whereas strong signaling of the PD-L1/PD-1 pathway can convert effector CD8 T cells into exhaustion. Importantly, CD8 T cells acquire overlapping, yet divergent molecular signatures depending on whether they are undergoing anergy, deletion, or exhaustion (35, 51). CD8 T cells undergoing deletion exhibit GzmB and Bcl-2 downregulation (35), whereas exhausted CD8 T cells overexpress several inhibitory receptors including PD-1 and have major changes in pathways of TCR and cytokine signaling (51). To address the molecular mechanisms of B7x-mediated inhibition of CD8 T cells, we compared the gene-expression profiles of Ag-specific pancreatic AI4αβ CD8 T cells. Unexpectedly, pancreatic CD8 T cells in diabetic AI4αβ mice and diabetes-free Rip-B7xAI4αβ mice had a similar pattern of global gene expression. CCL3 was the only gene whose expression was statistically higher in the AI4αβ T cells of Rip-B7xAI4αβ mice. In NOD mice, the temporal expression of CCL3 in the pancreas is associated with the development of T1D (52). In humans, serum level of CCL3 is increased whereas CCL2 is decreased in the islet autoantibody-positive group relative to the

---

**Figure 7.** Cytotoxic function, proliferation, and cell death of AI4αβ CD8 T cells. (A) AI4αβ CD8 T cell cytotoxic response toward target cells of MimA2 peptide-pulsed C57BL/6.H2b-k7 splenocytes. (B) Percentage of AI4αβ T cells that expressed Ki-67 in spleen, PLN, and pancreas from AI4αβ and RIP-B7xAI4αβ mice. AI4αβ CD8 T cells were determined by MimA2/H2-Db tetramer and anti-CD8 staining. (C) Percentage of cell death in AI4αβ CD8 T cells. Data are shown as means ± SEM and are representative of two to three independent experiments; n = 3–5 mice/group. *p < 0.05, **p < 0.01, Student t test.
autoantibody-negative group (53). These studies demonstrate that CCL3 expression increases during the progression to T1D. However, it is unclear whether increased CCL3 is a consequence of inflammation or CCL3 itself promotes disease during T1D development. Most mature hematopoietic cells including T cells and many tissue cells including β cells produce CCL3 (54), and whether this molecule produced by CD8 T cells has a role in the pathogenesis of diabetes is currently unknown and is open for further investigation with cell-type–specific, CCL3-deficient mouse models. Interestingly, a recent study shows that B7x-Ig protein prevents T cell proliferation and IL-2 production by inhibiting phosphorylation of ERK, JNK, p38, and AKT, but not LCK or ZAP-70 (55), suggesting that the B7x pathway is able to rapidly interfere with the activation state of some key kinases in the CD28 pathway without markedly changing gene transcription. Although pancreatic CD8 T cells in Rip-B7xAl4αβ mice were not under immune tolerance, because these cells were able to kill target cells very well, Al4αβ T cells in RIP-B7xAl4αβ mice showed less proliferation than those in Al4αβ mice. Moreover, Rip-B7x mice had fewer Al4 CD8 T cells in the pancreas in both spontaneous and adoptive transfer diabetes models. Therefore, what emerges is a model suggesting that B7x in the periphery prevents autoimmune diseases partially by limiting the proliferation of self-reactive, tissue-specific effector CD8 T cells in target tissues. Recent studies show that expression of B7x in islets or an insulinoma cell line prolongs allograft survival (56, 57), and that B7x-Ig fusion protein reduces diabetes incidence in NOD mice (58). Clearly, further studies on this new B7 pathway may lead to novel immunotherapy against autoimmune diseases.

Acknowledgments

We thank Bill Heath (University of Melbourne, Melbourne, VIC, Australia) for in vitro CTL generation, the Teresa Di Lorenzo laboratory (Albert Einstein College of Medicine) for technical help, and the National Institutes of Health Tetramer Core Facility for generating tetramer.

Disclosures

The authors have no financial conflicts of interest.

References

B7x PROTECTS FROM CD8 T CELL-MEDIATED DIABETES


Supplemental Information

B7x in the periphery abrogates pancreas specific damage mediated by self-reactive CD8 T cells

Jun Sik Lee, Lisa Scandiuzzi, Anjana Ray, Joyce Wei, Kimberly A. Hofmeyer, Yael M. Abadi, P’ng Loke, Juan Lin, Jianda Yuan, David V. Serreze, James P. Allison, Xingxing Zang

Supplemental Figure 1. Human APCs and T cell express B7-2 or B7-H1 (PD-L1) after stimuli. (A) B7-2 was up-regulated on human B cells after stimulation with LPS or PMA/ionomycin. (B) B7-H1 was up-regulated on human T cells after stimulation with PHA or PMA/ionomycin. (C) B7-H1 was up-regulated on human monocytes after stimulation with LPS/IFN-γ. (D) B7-2 expression was very low on human monocyte-derived immature DCs and was up-regulated on cytokine cocktail-, CD40L-,LPS-, or PMA/ionomycin-induced mature DCs. (E) B7-2 expression was low on human CD34-derived Langerhans cells (LCs) and was up-regulated on cytokine cocktail- or CD40L-induced mature LCs. (F) Anti-human B7x Abs stained B7x-transfected 293 cell line but not parent 239 line. Shaded histograms are isotype controls whereas open histograms are specific Abs against human B7, B7-H1 or B7x. Data represent one of two to four independent experiments.

Supplemental Figure 2. Mouse immune cells express PD-1 or PD-L2 after stimuli. (A) PD-1 was induced on mouse T cells activated with anti-CD3/CD28, ConA, or PMA/ionomycin. (B) PD-1 was induced on mouse B cells activated with anti-IgM F(ab’)2 fragment, LPS, or PMA/ionomycin. (C) Brugia malayi infection-induced alternatively activated macrophages and DCs expressed high levels of PD-L2. (D) Anti-mouse B7x Abs stained B7x-transfected BWZ cell line but not parent BWZ line. Shaded histograms are isotype controls whereas open histograms are specific Abs against mouse PD-1, PD-L2 or B7x. Data represent one of two to five independent experiments.
Supplemental Figure 1